CoChat
Sign Up
Cited by 1,090Schizophrenia research and treatmentPharmacology and Obesity TreatmentMental Health and Psychiatry

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

Open access
Pillinger, Toby, McCutcheon, Robert A, Vano, Luke, Mizuno, Yuya, Arumuham, Atheeshaan, Hindley, Guy, Beck, Katherine, Natesan, Sridhar, Efthimiou, Orestis, Cipriani, Andrea, Howes, Oliver D·2020·The Lancet Psychiatry
DOI 10.1016/s2215-0366(19)30416-xPMC PMC7029416
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Antipsychotic treatment is associated with metabolic disturbance. However, the degree to which metabolic alterations occur in treatment with different antipsychotics is unclear. Predictors of metabolic dysregulation are poorly understood and the association between metabolic change and change in psychopathology is uncertain. We aimed to compare and rank antipsychotics on the basis of their metabolic side-effects, identify physiological and demographic predictors of antipsychotic-induced metabolic dysregulation, and investigate the relationship between change in psychotic symptoms and change in metabolic parameters with antipsychotic treatment. METHODS: We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, randomised controlled trials comparing 18 antipsychotics and placebo in acute treatment of schizophrenia. We did frequentist random-effects network meta-analyses to investigate treatment-induced changes in body weight, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose concentrations. We did meta-regressions to examine relationships between metabolic change and age, sex, ethnicity, baseline weight, and baseline metabolic parameter level. We examined the association between metabolic change and psychopathology change by estimating the correlation between symptom severity change and metabolic parameter change. FINDINGS: (0·90 to 1·25) for olanzapine; for total-cholesterol from -0·09 mmol/L (-0·24 to 0·07) for cariprazine to 0·56 mmol/L (0·26-0·86) for clozapine; for LDL cholesterol from -0·13 mmol/L (-0.21 to -0·05) for cariprazine to 0·20 mmol/L (0·14 to 0·26) for olanzapine; for HDL cholesterol from 0·05 mmol/L (0·00 to 0·10) for brexpiprazole to -0·10 mmol/L (-0·33 to 0·14) for amisulpride; for triglycerides from -0·01 mmol/L (-0·10 to 0·08) for brexpiprazole to 0·98 mmol/L (0·48 to 1·49) for clozapine; for glucose from -0·29 mmol/L (-0·55 to -0·03) for lurasidone to 1·05 mmol/L (0·41 to 1·70) for clozapine. Greater increases in glucose were predicted by higher baseline weight (p=0·0015) and male sex (p=0·0082). Non-white ethnicity was associated with greater increases in total cholesterol (p=0·040) compared with white ethnicity. Improvements in symptom severity were associated with increases in weight (r=0·36, p=0·0021), BMI (r=0·84, p<0·0001), total-cholesterol (r=0·31, p=0·047), and LDL cholesterol (r=0·42, p=0·013), and decreases in HDL cholesterol (r=-0·35, p=0·035). INTERPRETATION: Marked differences exist between antipsychotics in terms of metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign profiles. Increased baseline weight, male sex, and non-white ethnicity are predictors of susceptibility to antipsychotic-induced metabolic change, and improvements in psychopathology are associated with metabolic disturbance. Treatment guidelines should be updated to reflect our findings. However, the choice of antipsychotic should be made on an individual basis, considering the clinical circumstances and preferences of patients, carers, and clinicians. FUNDING: UK Medical Research Council, Wellcome Trust, National Institute for Health Research Oxford Health Biomedical Research Centre.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30416-x

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Network graphs for weight, body-mass index, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and glucose Treatments with direct comparisons are linked with a line; the thickness of connecting lines corresponds to the number of trials evaluating the comparison.
Figure 1 Network graphs for weight, body-mass index, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and glucose Treatments with direct comparisons are linked with a line; the thickness of connecting lines corresponds to the number of trials evaluating the comparison.CC BY · PubMed Central
Figure 2 Forest plots for mean differences of antipsychotic drugs compared with placebo Colours indicate the confidence in the evidence for a given comparison: green is high, blue is moderate, yellow is low, and red is very low. Confidence of outcomes was graded using the Confidence in Network Meta-Analysis application. Grey lines immediately below each coloured line indicate the PI corresponding to that antipsychotic–placebo comparison. Full results for all treatment comparisons are shown in the appendix (pp 41-46). PI=prediction interval.
Figure 2 Forest plots for mean differences of antipsychotic drugs compared with placebo Colours indicate the confidence in the evidence for a given comparison: green is high, blue is moderate, yellow is low, and red is very low. Confidence of outcomes was graded using the Confidence in Network Meta-Analysis application. Grey lines immediately below each coloured line indicate the PI corresponding to that antipsychotic–placebo comparison. Full results for all treatment comparisons are shown in the appendix (pp 41-46). PI=prediction interval.CC BY · PubMed Central
Figure 3 Heat map of antipsychotic drugs ranked according to associated degree of alteration in bodyweight, body-mass index, and metabolic parameters Numbers reflect P-score, which rank antipsychotics on a continuous scale from 0 to 1. A higher P-score indicates a greater increase in the metabolic parameter, with the exception of HDL cholesterol, for which a higher P-score indicates a smaller increase. Grey squares indicate that data were not available.
Figure 3 Heat map of antipsychotic drugs ranked according to associated degree of alteration in bodyweight, body-mass index, and metabolic parameters Numbers reflect P-score, which rank antipsychotics on a continuous scale from 0 to 1. A higher P-score indicates a greater increase in the metabolic parameter, with the exception of HDL cholesterol, for which a higher P-score indicates a smaller increase. Grey squares indicate that data were not available.CC BY · PubMed Central
Figure 4 Bubble plots for meta-regressions on the effect of baseline predictors on antipsychotic-induced changes in fasting-glucose Each bubble corresponds to a study. The size of the bubble is proportional to the sample size. The solid line corresponds to the meta-regression estimate, and corresponding 95% CI, indicated by light-green shading.
Figure 4 Bubble plots for meta-regressions on the effect of baseline predictors on antipsychotic-induced changes in fasting-glucose Each bubble corresponds to a study. The size of the bubble is proportional to the sample size. The solid line corresponds to the meta-regression estimate, and corresponding 95% CI, indicated by light-green shading.CC BY · PubMed Central
Figure 5 Bubble plots for the associations between change in symptom severity and change in metabolic parameters Each bubble corresponds to a study. The size of the bubble is proportional to the sample size. The solid line corresponds to the meta-regression estimate, and corresponding 95% CI, indicated by light-green shading. SMD=standard mean difference.
Figure 5 Bubble plots for the associations between change in symptom severity and change in metabolic parameters Each bubble corresponds to a study. The size of the bubble is proportional to the sample size. The solid line corresponds to the meta-regression estimate, and corresponding 95% CI, indicated by light-green shading. SMD=standard mean difference.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Sorted by citations

Items 701–800 of 1,000

Related

See all

Metadata

Authors
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D.
Affiliations
  • King's College London (GB)
  • University of Bern (CH)
  • Oxford Health NHS Foundation Trust (GB)
Corresponding author
Pillinger, Toby
ORCID
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2020-01
Volume
7
Issue
1
Pages
64-77
ISSN
2215-0366 (ISSN-L)
DOI
10.1016/s2215-0366(19)30416-x
PMC
PMC7029416
OpenAlex
W2982167270
Cited by
1,090
References
46
Citations by year
2026: 213 · 2025: 204 · 2024: 172 · 2023: 163 · 2022: 145 · 2021: 129 · 2020: 58
FWCI
14.06
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • BORIS (University Library Bern) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Open Access CRIS of the University of Bern
Funders
  • Medical Research Council (MC-A656-5QD30)
  • Brain and Behavior Research Foundation
  • National Institute for Health and Care Research
  • South London and Maudsley NHS Foundation Trust
  • King&apos;s College London (200102/Z/15/Z)
  • Royal College of Psychiatrists
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (180083)
  • Wellcome Trust (094849/Z/10/Z)
  • NIHR Oxford Biomedical Research Centre (BRC-1215-20005)
  • Maudsley Charity (666)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
antipsychotic drugs, schizophrenia, metabolic dysfunction, antipsychotic-induced metabolic side effects, body weight, body mass index, lipid profile, cholesterol, triglycerides, blood glucose, psychopathology, olanzapine, clozapine, cariprazine, brexpiprazole, amisulpride, atypical antipsychotics
MeSH terms
Blood Glucose, Humans, Schizophrenia, Antipsychotic Agents, Weight Gain, Body Mass Index, Randomized Controlled Trials as Topic, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review